Statements


American College of Medical Genetics and Genomics (ACMG)

"Noninvasive prenatal screening using cell-free DNA (NIPS) has been rapidly integrated into prenatal care since the initial American College of Medical Genetics and Genomics (ACMG) statement in 2013. New evidence strongly suggests that NIPS can replace conventional screening for Patau, Edwards, and Down syndromes across the maternal age spectrum, for a continuum of gestational age beginning at 9–10 weeks..."

http://capsprenatal.com/Resources/ACMG_Policy Statement_NIPS.pdf


The American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM)

"Screening tests for aneuploidy are now available for pregnant women in all trimesters of pregnancy. Among these are first-trimester, triple, quad, and penta screens; cell-free DNA; and ultrasonographic screening as single screening tests."

http://capsprenatal.com/Resources/ACOG_PB_163 Aneuploidy_Screening.pdf


International Society for Prenatal Diagnosis (ISPD)

"The following protocol options are currently considered appropriate: cfDNA screening as a primary test offered to all pregnant women..."

http://capsprenatal.com/Resources/ISPD_PositionStatement_Current_8Apr2015.pdf